Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

October 15, 2021

Study Completion Date

October 26, 2021

Conditions
Chorea, Huntington
Interventions
DRUG

Valbenazine

vesicular monoamine transporter 2 (VMAT2) inhibitor

DRUG

Placebo

non-active dosage form

Trial Locations (46)

14221

Neurocrine Clinical Site, Williamsville

14618

Neurocrine Clinical Site, Rochester

15213

Neurocrine Clinical Site, Pittsburgh

20007

Neurocrine Clinical Site, Washington D.C.

22908

Neurocrine Clinical Site, Charlottesville

27705

Neurocrine Clinical Site, Durham

29203

Neurocrine Clinical Site, Columbia

29425

Neurocrine Clinical Site, Charleston

29615

Neurocrine Clinical Site, Greenville

30329

Neurocrine Clinical Site, Atlanta

32608

Neurocrine Clinical Site, Gainesville

33136

Neurocrine Clinical Site, Miami

35233

Neurocrine Clinical Site, Birmingham

37212

Neurocrine Clinical Site, Nashville

40202

Neurocrine Clinical Site, Louisville

43210

Neurocrine Clinical Site, Columbus

43614

Neurocrine Clinical Site, Toledo

44195

Neurocrine Clinical Site, Cleveland

46202

Neurocrine Clinical Site, Indianapolis

48109

Neurocrine Clinical Site, Ann Arbor

48322

Neurocrine Clinical Site, West Bloomfield

52242

Neurocrine Clinical Site, Iowa City

58103

Neurocrine Clinical Site, Fargo

60611

Neurocrine Clinical Site, Chicago

60612

Neurocrine Clinical Site, Chicago

66160

Neurocrine Clinical Site, Kansas City

67226

Neurocrine Clinical Site, Wichita

68198

Neurocrine Clinical Site, Omaha

70121

Neurocrine Clinical Site, New Orleans

72205

Neurocrine Clinical Site, Little Rock

77054

Neurocrine Clinical Site, Houston

80045

Neurocrine Clinical Site, Aurora

80113

Neurocrine Clinical Site, Englewood

84108

Neurocrine Clinical Site, Salt Lake City

92037

Neurocrine Clinical Site, La Jolla

95817

Neurocrine Clinical Site, Sacramento

98195

Neurocrine Clinical Site, Seattle

99202

Neurocrine Clinical Site, Spokane

02118

Neurocrine Clinical Site, Boston

02215

Neurocrine Clinical Site, Boston

02129

Neurocrine Clinical Site, Charlestown

05401

Neurocrine Clinical Site, Burlington

V6T 2B5

Neurocrine Clinical Site, Vancouver

K1Y 4E9

Neurocrine Clinical Site, Ottawa

M2K 1E1

Neurocrine Clinical Site, Toronto

M3B 2S7

Neurocrine Clinical Site, Toronto

Sponsors
All Listed Sponsors
collaborator

Huntington Study Group

NETWORK

lead

Neurocrine Biosciences

INDUSTRY